PURPOSE: Embryological and clinical efficacy of gonadotropin-releasing hormone (GnRH) antagonist and agonist stimulation protocols in non-obese women with polycystic ovarian syndrome (PCOS) were compared. METHODS: A prospective randomized study. SETTING: Medical University Hospital. PATIENTS: 70 infertile PCOS patients; 33 in GnRH antagonist and 37 in GnRH agonist group. RESULTS:Similar mature metaphase II oocyte rate (76% vs. 76%) was observed in both protocols. Optimal pronuclear morphology zygotes dominated in both groups (64% vs. 66%). Transferred embryo quality did not differ in both protocols. No significant differences between both protocols were found in delivery rate (p = 0.481), pregnancy rate (p = 0.810), multiple pregnancy rate (p = 0.501), miscarriage rate (p = 0.154), fertilization rate (p = 0.388) and implantation rate (p = 1.000). Duration of stimulation and total follicle-stimulating hormone (FSH) dose were significantly lower in GnRH antagonist protocol (p = 0.0005). CONCLUSIONS:GnRH antagonist and agonist protocols in non-obese PCOS patients yield similar embryological and clinical outcomes. Shorter duration of treatment and lower FSH requirement in GnRH antagonist group may be financially beneficial and therefore attractive for patients.
RCT Entities:
PURPOSE: Embryological and clinical efficacy of gonadotropin-releasing hormone (GnRH) antagonist and agonist stimulation protocols in non-obesewomen with polycystic ovarian syndrome (PCOS) were compared. METHODS: A prospective randomized study. SETTING: Medical University Hospital. PATIENTS: 70 infertile PCOSpatients; 33 in GnRH antagonist and 37 in GnRH agonist group. RESULTS: Similar mature metaphase II oocyte rate (76% vs. 76%) was observed in both protocols. Optimal pronuclear morphology zygotes dominated in both groups (64% vs. 66%). Transferred embryo quality did not differ in both protocols. No significant differences between both protocols were found in delivery rate (p = 0.481), pregnancy rate (p = 0.810), multiple pregnancy rate (p = 0.501), miscarriage rate (p = 0.154), fertilization rate (p = 0.388) and implantation rate (p = 1.000). Duration of stimulation and total follicle-stimulating hormone (FSH) dose were significantly lower in GnRH antagonist protocol (p = 0.0005). CONCLUSIONS:GnRH antagonist and agonist protocols in non-obese PCOSpatients yield similar embryological and clinical outcomes. Shorter duration of treatment and lower FSH requirement in GnRH antagonist group may be financially beneficial and therefore attractive for patients.
Authors: Péter Fedorcsák; Per Olav Dale; Ritsa Storeng; Gudvor Ertzeid; Sverre Bjercke; Nan Oldereid; Anne K Omland; Thomas Abyholm; Tom Tanbo Journal: Hum Reprod Date: 2004-08-19 Impact factor: 6.918
Authors: Mostafa I Abuzeid; Mohamed Mitwally; Yasmine M Abuzeid; Hammad A Bokhari; Mohammad Ashraf; Michael P Diamond Journal: J Assist Reprod Genet Date: 2012-09-08 Impact factor: 3.412
Authors: M F Costello; M L Misso; A Balen; J Boyle; L Devoto; R M Garad; R Hart; L Johnson; C Jordan; R S Legro; R J Norman; E Mocanu; J Qiao; R J Rodgers; L Rombauts; E C Tassone; S Thangaratinam; E Vanky; H J Teede Journal: Hum Reprod Open Date: 2019-01-04